ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1236 • ACR Convergence 2023

    Melanoma Differentiation-Associated Protein-5 in Juvenile Dermatomyositis: A Single Center Cohort

    Dawn Gist1, Sarah Molina2, Maria Pereira3, Andrea Ramirez3, Cagri Yildirim-Toruner4 and Marietta De Guzman3, 1Baylor College of Medicine Pediatrics Residency, Houston, TX, 2Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, 3Baylor College of Medicine, Houston, TX, 4Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy that causes muscle weakness, rash, vascular changes, or other organ involvement. The phenotypes may vary, and…
  • Abstract Number: 1074 • ACR Convergence 2023

    Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

    Laura Cappelli1, omer Kamal2, Michelle Jones3, Clifton Bingham4 and Ami Shah5, 1Johns Hopkins School of Medicine, Baltimore, MD, 2St. Agnes Hospital, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Johns Hopkins University, Baltimore, MD, 5Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD

    Background/Purpose: Immune checkpoint inhibitors (ICI) can cause inflammatory arthritis (IA) of varying severity. Many patients with ICI-IA require immunosuppression beyond corticosteroids, but there is no…
  • Abstract Number: 1238 • ACR Convergence 2023

    Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)

    Oscar Mwizerwa1, Andrea Knight2, Daniela Dominguez2, Deborah Levy2, Holly Convery2, Kendal Thompson2, Nicholas Gold2, Catherine M Walsh2 and Linda Hiraki2, 1University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) and celiac disease (CD) are autoimmune diseases characterized by the presence of specific autoantibodies. We aimed to investigate the prevalence…
  • Abstract Number: 1206 • ACR Convergence 2023

    Self-Perceptions of Aging and Physical Activity in Older Adults with Arthritis: Does General Health Matter?

    Sarah Lieber1, Jerad Moxley2, Lisa Mandl1, M. Carrington Reid2 and Sara Czaja2, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Weill Cornell Medicine, New York, NY

    Background/Purpose: Negative self-perceptions of aging are generally associated with decreased physical function in older adults. Whether self-perceptions of aging (i.e., "awareness of age-related change" including…
  • Abstract Number: 1095 • ACR Convergence 2023

    Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures

    Emma Kersey1, Jing Li1, Julia Kay1, Julia Adler-Milstein1, Jinoos Yazdany2 and Gabriela Schmajuk3, 1University of California San Francisco, San Francisco, CA, 2University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 3UCSF / SFVA, San Francisco, CA

    Background/Purpose: The American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) EHR-based registry facilitates quality measure calculation and reporting for rheumatology practices in national…
  • Abstract Number: 1147 • ACR Convergence 2023

    Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function

    Helena Port I Linares1, Birte Coppers2, Sara Bayat2, Godonou Elie-Tino2, Larissa Valor-Mendez2, David Simon2, Filippo Fagni2, Giulia Corte2, Anne-Christine Bay-Jensen3, Koray Tascilar2, Axel Hueber4, Verena Schoenau2, Michael Sticherling5, Simon Heinrich6, Daniela Bohr2, Georg Schett7, Arnd Kleyer8, Sigrid Leyendecker6, Signe Holm Nielsen3 and Anna-Maria Liphardt9, 1Nordic Bioscience A/S / University of Copenhagen, Copenhagen, Denmark, 2Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 3Nordic Bioscience, Herlev, Denmark, 4Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University / Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Nürnberg, Germany, 5Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany, 6Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Institute of Applied Dynamics, Erlangen, Germany, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8University Hospital Erlangen, Erlangen, Germany, 9Friedrich-Alexander-University Erlangen-Nuremberg, Internal Medicine 3 - Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: Inflammatory musculoskeletal diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterized by physical function impairment due to progressive inflammatory and structural changes.…
  • Abstract Number: 1162 • ACR Convergence 2023

    Serial Imaging Changes in Skeletal Muscle Composition and Their Association with Clinical Outcomes in Idiopathic Inflammatory Myopathies

    Mamatha Gorijavolu1, Chengappa Kavadichanda1, Ramesh Ananthakrishnan1, Christina Mariaselvam1, Molly Thabah1 and VS Negi2, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 2All India Institute of Medical Sciences, Bilaspur, Puducherry, India

    Background/Purpose: Muscle weakness in inflammatory myopathies (IIM) is due to muscle-edema, atrophy and fatty-infiltration among which edema is the predominant cause at baseline. Some IIM…
  • Abstract Number: 1245 • ACR Convergence 2023

    Evaluating a Diagnostic Algorithm for Childhood Sjögren’s Disease

    Sara Stern1, Matthew Basiaga2, Linda Amoafo1, Seunghee Cha3, Akaluck Thatayatikom4, Erin Treemarcki1, Rachel Randell5, Brian Dizon6, Jamie Diianni7, Sharon Tiger8, Janet Orrock9, Simone Appenzeller10, Cuoghi Edens11 and Scott Lieberman12, 1University of Utah School of Medicine, Salt Lake City, UT, 2Mayo Clinic, Rochester, MN, 3Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry and Center for Orphaned Autoimmune Disorders (COAD), Gainesville, FL, 4AdventHealth for Children, Orlando, FL, Orlando, FL, 5Duke University School of Medicine, Durham, NC, 6National Institute of Arthritis and Musculoskelatal and Skin Diseases, Bethesda, MD, 7Childhood Arthritis and Rheumatology Research Alliance (CARRA), Washington, DC, 8Childhood Arthritis and Rheumatology Research Alliance (CARRA), Beltsville, MD, 9The University of Texas at Austin Dell Medical School, Austin, TX, 10UNICAMP, Campinas, Brazil, 11University of Chicago, Chicago, IL, 12University of Iowa Carver College of Medicine, Iowa City, IA

    Background/Purpose: There are no widely accepted diagnostic or classification criteria for childhood Sjögren's disease (cSjD). To address the urgent need for consensus, the Childhood Arthritis…
  • Abstract Number: 0802 • ACR Convergence 2023

    Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells

    Samuel Kemble1, Christopher Mahony2, Charlotte Smith2, Joel Rurik3, Haig Aghajanian3, Jonathan Epstein3, Mark Coles4 and Adam Croft2, 1University Birmingham, Rugeley, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4University of Oxford, Oxford, United Kingdom

    Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…
  • Abstract Number: 1172 • ACR Convergence 2023

    Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse

    Hideaki Tsuji1, Fabricio Espinosa-Ortega2, Maryam Dastmalchi2, Ingrid Lundberg2 and Karin Lodin3, 1Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Huddinge, Sweden

    Background/Purpose: Our aim was to explore whether maintenance of remission in patients with idiopathic inflammatory myopathy (IIM) depends on glucocorticoids (GCs) after achieving remission. Therefor…
  • Abstract Number: 1177 • ACR Convergence 2023

    Anti-HMGCR Autoantibody Levels in the Follow-up of Statin-induced Immune-mediated Necrotizing Myopathy: Multicentric Study of 24 Patients

    David Martinez-Lopez1, Cristina Corrales Selaya2, Diana Prieto-Peña2, Piotr Szczesny3, Antonella Notarnicola4, Marcos Lopez-Hoyos5, Ricardo Blanco6, Ingrid Lundberg7 and Maryam Dastmalchi7, 1Hospital de Sierrallana, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland; Department of Neurology, Medical University of Warsaw, Warsaw, Poland, 4Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 5Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, 6Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 7Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden

    Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies. It is characterized by elevated creatine kinase (CK) levels, and severe muscle…
  • Abstract Number: 1247 • ACR Convergence 2023

    Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial

    Hermine Brunner1, Diego Oscar Viola2, Richard Dimelow3, Inmaculada Calvo Penadés4, Christel Wilkinson5, Juan Cruz Rizo Rodriguez6, Alina Boteanu7, Sylvia Kamphuis8, Kirsten Minden9, Gerd Horneff10, Jordi Anton11, Masaaki Mori12, Yuichi Yamasaki13, Jose Miyar Olaiz14, Rebecca Marino15, Andre van Maurik16, Mohamed Okily17, Emad Yanni18 and Paul WIlde19, 1Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 2CAICI Institute, Pediatric Rheumatology, Santa Fe, Argentina, 3GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation, Stevenage, United Kingdom, 4Hospital Universitario y Politécnico La Fe, Pediatric Rheumatology Unit, València, Spain, 5GlaxoSmithKline, Clinical Statistics, Stevenage, United Kingdom, 6Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, San Luis Potosí, Mexico, 7Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, 8Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, 9Charité Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany, 10Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, 11Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, 12Tokyo Medical and Dental University Hospital, Department of Lifetime Clinical Immunology, Tokyo, Japan, 13Kagoshima University Hospital, Department of Pediatrics, Kagoshima, Japan, 14GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, 15GlaxoSmithKline, Safety Evaluation and Risk Management, Durham, NC, 16GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Brentford, United Kingdom, 17GlaxoSmithKline, Clinical Development, ImmunoInflammation, Brentford, United Kingdom, 18GlaxoSmithKline, Clinical Development, Rockville, MD, 19GlaxoSmithKline, Clinical Development, Brentford, United Kingdom

    Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…
  • Abstract Number: 0813 • ACR Convergence 2023

    Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants

    Mariano Andrés1, Nalia Domínguez-Lirón2, Enrique Calvo-Aranda3, Esther Vicente Rabaneda4, Agustín Martínez-Sanchís1, Francisca Sivera5, Diana Peiteado6, Alejandro Prada7, Blanca Garcia8, Basilio Rodríguez9, BORIS ANTHONY BLANCO CACERES10, José Antonio Bernal11, Santos Castañeda12, Laura Barrio7, Sonia Minguez9, Mónica Vázquez Díaz13, José Miguel Senabre11, Cristina Bohorquez14, Silvia Gómez-Sabater15, Rocío Caño-Alameda15 and Eugenio De Miguel16, 1Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 2Miguel Hernández University, Alicante, Spain, 3Hospital Universitario Infanta Leonor, Madrid, Spain, 4Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 5Elda General University Hospital, Elda, Spain, 6Hospital La Paz, Madrid, Spain, 7Hospital Universitario de Torrejón, Madrid, Spain, 8Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 9Fundació Althaia, Manresa, Spain, 10Hospital Universitario Ramon y Cajal, Madrid, Spain, 11Hospital Marina Baixa, Villajoyosa, Spain, 12Hospital Universitario de la Princesa, Madrid, Spain, 13Hospital Ramon y Cajal, Madrid, Spain, 14Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, 15Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, 16Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: The prevalence of sonographic monosodium urate (MSU) crystal deposition and inflammation in patients with gout in remission is unknown. In 2022, we reported a…
  • Abstract Number: 0363 • ACR Convergence 2023

    Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort

    Michael Matt1, Daniel Drozdov1, Rolla Abu-Arja2, Shanmuganathan Chandrakasan3, Kyla Driest2, Elvira Cannizzaro Schneider4, Despina Moshous5, Benedicte Neven5, Karen Onel6, Sampath Prahalad7, Susan Prockop8, Pierre Quartier5, Johannes Roth9, Donna Wall10, Ulrike Zeilhofer11, Scott Canna12, Alexei Grom1, Grant Schulert1 and Rebecca Marsh1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Emory University School of Medicine, Atlanta, GA, 4Universitaetskinderspital Zurich, Zurich, Switzerland, 5Paris Cité Université and Necker Hospital, Paris, France, 6Hospital for Special Surgery, New York, NY, 7Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA, 8Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, 9University of Ottawa, Ottawa, ON, Canada, 10The Hospital for Sick Children, Toronto, ON, Canada, 11Children's Hospital of Zurich, Zurich, Switzerland, 12Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Refractory systemic juvenile idiopathic arthritis (sJIA) in children can be complicated by repeated episodes of macrophage activation syndrome (MAS) or sJIA-related lung disease (sJIA-LD).…
  • Abstract Number: 1090 • ACR Convergence 2023

    Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center

    Shelby Gomez1, Trisha Ludwig1, Katherine Hartkopf2, Sancia Ferguson3, Lori Zemlicka4, Mindy Jones5 and Christie M. Bartels6, 1UW Health Pharmacy, Madison, WI, 2Pharmacy Society of Wisconsin, Madison, WI, 3University of Wisconsin, Madison, WI, 4UW Health, Madison, WI, 5Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 6University of Wisconsin, School of Medicine and Public Health, Madison, WI

    Background/Purpose: We embedded a clinical pharmacist into our university rheumatology clinics beginning in June 2022 to improve patient experience and reduce provider burden based on…
  • « Previous Page
  • 1
  • …
  • 246
  • 247
  • 248
  • 249
  • 250
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology